Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, ...

Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a ...

This big pharma stock should be even more appealing to investors amid market turbulence.

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...

Remember Pfizer (NYSE: PFE), the giant pharmaceutical company that developed a COVID-19 vaccine within weeks of the pandemic hitting U.S. shores and got it approved within a year? It was the fastest ...

Investors continued to be positive on the pharmaceutical giant following a deal reached with the government. Among other benefits, it will have a reprieve from potential tariffs on its industry. On ...